Pay in 4 interest-free payments of $7.31 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Currently approved weight management pharmacotherapy in the UK includes: Semaglutide (Wegovy) a GLP-1 receptor agonist approved by the MHRA for chronic weight management in adults, subject to NICE Technology Appraisal eligibility criteria [3] [5] Tirzepatide (Mounjaro) a dual GIP/GLP-1 receptor agonist approved by the MHRA for the treatment of type 2 diabetes
The most common side effects of GLP-1 are gastrointestinal issues, and some foods may be more likely to increase nausea and stomach discomfort than others while using these meds
Integrating Diet and Physical Activity When Prescribing GLP-1sLifestyle Factors Remain Crucial
This science-forward approach ensures that you are supporting your body with the highest quality ingredients available
Discontinuation Rates Discontinuation rates due to adverse events in the Phase 2 trial were dose-dependent, ranging from approximately 6% in the 1 mg arm to 16% in the 12 mg arm
